Clearmind Medicine Begins Enrolling Patients At Tel Aviv Sourasky Medical Center As New Site Joins Its Phase I/IIa Trial For Alcohol Use Disorder

Clearmind Medicine Inc., a clinical-stage biotechnology company developing novel neuroplastogen-based treatments for major unmet health needs, announced that Tel Aviv Sourasky Medical Center (TASMC), one of Israel’s leading academic hospitals, has officially begun patient enrollment for the company’s FDA-approved multinational Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD). The site successfully recruited its first participant, marking the full activation of this important Israeli center.

The enrollment milestone was achieved under the leadership of Prof. David Zeltser, Director of the Internal Medicine Department and Deputy Director of R&D and Innovation at TASMC. With this development, TASMC joins a growing group of prominent global institutions that are screening and enrolling participants in the study, including Yale School of Medicine, Johns Hopkins University School of Medicine, and Hadassah Medical Center.

The ongoing Phase I/IIa trial is designed to assess the safety, tolerability, pharmacokinetics, and early signs of efficacy of CMND-100, Clearmind’s proprietary non-hallucinogenic MEAI-based oral compound. Initial top-line data from the first completed cohort indicated strong safety and adherence, with no serious adverse events reported.

Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, highlighted the importance of this progress, noting that the first patient enrollment at TASMC represents a meaningful step forward in the global advancement of the trial. She expressed appreciation for Prof. Zeltser and the TASMC team, adding that the company remains committed to advancing CMND-100 as a potentially transformative therapy for Alcohol Use Disorder.